Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2012
- Operating Profit Margin since 2012
- Price to Earnings (P/E) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The overall liquidity position is characterized by a pattern of initial stability, a significant downturn starting in mid-2024, and a gradual recovery entering 2026. Across the entire period, all primary liquidity metrics remain below 1.0, signifying that current liabilities consistently exceed current assets.
- Current Ratio
- The current ratio fluctuated between a peak of 0.96, maintained across several quarters between September 2022 and September 2023, and a low of 0.65 in September 2024. A period of relative stability was observed through early 2024 before a sharp decline occurred during the second and third quarters of that year. A moderate recovery trend is evident from early 2025, culminating in a ratio of 0.80 by March 2026.
- Quick Ratio
- A consistent gap is maintained between the current and quick ratios, reflecting the impact of non-quick current assets on overall liquidity. The ratio reached a peak of 0.72 in March 2024 but experienced a substantial contraction to 0.41 by December 2025. Similar to the trend seen in the current ratio, a rebound is noted in the first quarter of 2026, returning the ratio to 0.52.
- Cash Ratio
- The cash ratio exhibits the highest degree of volatility, reaching a peak of 0.44 in March 2024. Following this peak, a precipitous decline occurred throughout 2024 and 2025, reaching a period low of 0.12 in December 2025. This indicates a significant reduction in immediate cash availability relative to current liabilities before a recovery to 0.22 in March 2026.
The synchronized decline across all three ratios during 2024 and 2025 suggests a period of increased short-term obligations or a strategic reallocation of liquid assets. The convergence of these metrics at their lowest points in late 2025, followed by a simultaneous uptick in early 2026, points toward a cyclical shift in the short-term financial positioning.
Current Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile of the organization is characterized by a current ratio that remained consistently below 1.0 throughout the analyzed period from March 2022 to March 2026. This indicates a persistent working capital deficit where current liabilities exceeded current assets across all reporting quarters.
- Current Ratio Volatility
- The current ratio exhibited three distinct phases. An initial improvement phase occurred between March 2022 and December 2022, where the ratio rose from 0.82 to 0.96. This was followed by a period of relative stability through March 2024, maintaining a range between 0.81 and 0.96. A significant decline was observed starting in June 2024, with the ratio reaching a period low of 0.65 in September 2024 and remaining suppressed below 0.80 until a slight recovery to 0.80 in March 2026.
- Current Liabilities Trajectory
- There is a clear upward trend in current liabilities over the long term. Obligations increased from 32,521 million USD in March 2022 to a peak of 43,289 million USD in December 2025. The most aggressive expansion of liabilities occurred between March 2024 and September 2024, contributing heavily to the deterioration of the liquidity ratio during that window.
- Current Asset Fluctuations
- Current assets demonstrated significant volatility rather than a linear trend. Assets peaked at 38,871 million USD in March 2024, but subsequently contracted sharply to 25,582 million USD by December 2024. This contraction, occurring simultaneously with rising liabilities, resulted in the lowest recorded liquidity levels. A modest recovery in asset levels followed in 2025 and early 2026, ending at 33,529 million USD.
- Liquidity Correlation
- The divergence between asset and liability growth reached its maximum point in the latter half of 2024 and throughout 2025. The pressure on the current ratio was most acute when liabilities climbed above 40,000 million USD while assets failed to maintain a commensurate level of growth, suggesting a period of heightened reliance on short-term financing or operational cash flow to meet immediate obligations.
Quick Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and equivalents | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position experienced significant volatility between March 2022 and March 2026, characterized by a period of strengthening followed by a notable contraction and a subsequent partial recovery.
- Quick Ratio Trend Analysis
- The quick ratio demonstrated an upward trajectory from March 2022, rising from 0.52 to a peak of 0.72 by March 2024. This period represents the strongest liquidity phase within the observed timeframe. However, a sharp decline occurred thereafter, with the ratio falling to 0.43 by September 2024 and reaching a nadir of 0.41 in December 2025. By March 31, 2026, the ratio recovered to 0.52, returning to its initial 2022 baseline.
- Quick Assets Dynamics
- Total quick assets showed substantial growth in the first half of the period, climbing from 16,831 million USD in March 2022 to a maximum of 30,016 million USD in March 2024. A rapid depletion of these assets followed, with levels dropping to 16,443 million USD by December 2024. Throughout 2025, quick assets remained relatively suppressed, fluctuating between 17,652 million USD and 19,104 million USD, before increasing to 21,870 million USD in the final quarter.
- Current Liabilities Evolution
- Current liabilities remained relatively stable between 27,590 million USD and 34,773 million USD from March 2022 through September 2023. A structural increase in obligations began in March 2024, with liabilities rising above 41,000 million USD and peaking at 43,289 million USD in December 2025. The simultaneous increase in liabilities and the decrease in quick assets during 2024 and 2025 exerted significant downward pressure on the quick ratio.
- Liquidity Correlation and Insights
- The divergence between asset levels and liability obligations became most acute between March 2024 and December 2025. The contraction of the quick ratio during this window suggests a reduced capacity to meet short-term obligations using only the most liquid assets. The recovery observed in March 2026 is primarily attributable to a rise in total quick assets to 21,870 million USD coupled with a slight reduction in current liabilities to 42,100 million USD.
Cash Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cash and equivalents | |||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile demonstrates a period of significant volatility, characterized by a strong upward trajectory in the cash ratio through early 2024, followed by a pronounced contraction and a subsequent partial recovery in early 2026.
- Total Cash Asset Trends
- Cash reserves exhibited substantial fluctuations over the analyzed timeframe. Assets increased from 6,098 million in March 2022 to a peak of 18,067 million in March 2024. A sharp decline followed, with cash positions dropping to a low of 5,175 million by March 2025, before rebounding to 9,391 million by March 2026.
- Current Liability Progression
- A consistent long-term increase in current liabilities is observed. Short-term obligations rose from 32,521 million in March 2022 to a peak of 43,289 million in December 2025. This steady growth in liabilities exerted downward pressure on liquidity ratios, particularly during periods of declining cash balances.
- Cash Ratio Dynamics
- The cash ratio peaked at 0.44 in March 2024, indicating the strongest immediate liquidity position within the period. However, a sustained decline occurred throughout the remainder of 2024 and 2025, reaching a minimum of 0.12 in December 2025. This deterioration was driven by the simultaneous reduction in cash assets and the expansion of current liabilities. By March 31, 2026, the ratio recovered to 0.22, reflecting an improved ability to meet short-term obligations compared to the 2025 lows.